Mylan boosted EpiPen’s price amid bonus target for execs

As Mylan was jacking up the price of EpiPens over the past two years, the drugmaker was also planning to boost something else: its top exeutives’ pay. In 2014, Mylan adopted a one-time incentive plan for about 100 top executives that promised to reward them if the company could reach adjusted per-share earnings of $6 by 2018. At the time, the bonuses were worth $82 million to its five top executives alone, according to The Wall Street Journal. Since the plan was adopted, Mylan has doubled